Astrazeneca (AZN) Equity Ratio (2011 - 2025)

Astrazeneca (AZN) has reported Equity Ratio for 18 consecutive years, with 0.42 the latest figure, recorded in Q1 2026.

• In Q1 2026, Equity Ratio rose 7.48% year-over-year to 0.42; the TTM figure through Mar 2026 stood at 0.42 (up 7.48% YoY), while the FY2025 annual figure was 0.43, up 8.6% from the prior year.
• Equity Ratio came in at 0.42 for Q1 2026 at Astrazeneca, down from 0.43 in the prior quarter.
• The five-year high for Equity Ratio was 125.13 in Q4 2023, with the low at 0.36 in Q1 2022.
• Average Equity Ratio over 5 years is 7.72, with a median of 0.39 recorded in 2023.
• Across the five-year window, Equity Ratio sank 99.9% in 2022 and jumped 32478.7% in 2023, its largest moves.
• Year by year, Equity Ratio stood at 0.38 in 2022, then surged by 32478.7% to 125.13 in 2023, then slumped by 99.69% to 0.39 in 2024, then increased by 8.6% to 0.43 in 2025, then retreated by 2.69% to 0.42 in 2026.
• According to Business Quant data, Equity Ratio over the past three periods registered 0.42, 0.43, and 0.4 for Q1 2026, Q4 2025, and Q3 2025 respectively.